SCHEMBL2593064

SCHEMBL2593064

OC1COc2c(F)cccc21

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.41
ADRA2A P08913 1/20 0.39
TERT O14746 1/20 0.38
TAAR1 Q96RJ0 2/20 0.37
CYP2D6 P10635 1/20 0.37
CA2 P00918 1/20 0.36
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
KDM1A O60341 2/20 0.33
KDM1B Q8NB78 1/20 0.33
ACHE P22303 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAP3K14 Q99558 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22143945 0.81 ADRA2A (0.50) ADRA2ATERTMAP3K14
SCHEMBL4755702 0.81 ADRA2A (0.50) ADRA2ATERTMAP3K14
SCHEMBL1743731 0.81 MAP3K14 (0.43) ADRA2ATAAR1HTR2CHTR2BACHE
SCHEMBL6900041 0.79 CYP19A1 (0.37) CYP19A1ADRA2ATERTTAAR1CYP2D6
SCHEMBL1979378 0.79 CYP19A1 (0.37) CYP19A1ADRA2ATERTTAAR1CYP2D6
SCHEMBL1979379 0.79 CYP19A1 (0.37) CYP19A1ADRA2ATERTTAAR1CYP2D6
SCHEMBL13834855 0.79 CYP19A1 (0.37) CYP19A1ADRA2ATERTTAAR1CYP2D6
SCHEMBL13518747 0.78 ACHE (0.51) CA2HTR2CHTR2BACHECHRNB2
SCHEMBL13519097 0.77 HTR2B (0.41) ADRA2AHTR2CHTR2BTRPM8KDM1A
SCHEMBL31278211 0.77 KDM1A (0.41) CYP19A1ADRA2ATERTTAAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724127-B Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof 中国科学院上海药物研究所 2023-02-17 CN disclosed
US-20230032101-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-02-02 US disclosed
US-20230032101-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-02-02 US disclosed
EP-4053124-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2022-09-07 EP disclosed
EP-4053124-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2022-09-07 EP disclosed
CN-114829357-A Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof 中国科学院上海药物研究所 2022-07-29 CN disclosed
WO-2021083060-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF 中国科学院上海药物研究所 2021-05-06 WO disclosed
WO-2021083060-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF 中国科学院上海药物研究所 2021-05-06 WO disclosed
CN-112724127-A Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof 中国科学院上海药物研究所 2021-04-30 CN disclosed
EP-2566862-B1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
EP-2566862-B1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
US-8729084-B2 Benzofuranyl analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-20 US disclosed
US-8729084-B2 Benzofuranyl analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-20 US disclosed
US-8729084-B2 Benzofuranyl analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-20 US disclosed
EP-2566862-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS Bristol-Myers Squibb Company (US) 2013-03-13 EP disclosed
US-20130059858-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-07 US disclosed
US-20130059858-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-07 US disclosed
US-20130059858-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-07 US disclosed
WO-2011140161-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 WO disclosed
WO-2011140161-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230032101-A1 FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF STING1, CGAS, IRF3 CYP19A1 1347/4885ADRA2A 1565/4885TERT 4842/4885
US-20130059858-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS GPR119, GPR180, GPR139 CYP19A1 1498/4885ADRA2A 135/4885TERT 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.